Invention Grant
- Patent Title: Neutralization of inhibitory pathways in lymphocytes
-
Application No.: US15511778Application Date: 2015-09-15
-
Publication No.: US10711063B2Publication Date: 2020-07-14
- Inventor: Pascale Andre , Mathieu Blery , Carine Paturel , Nicolai Wagtmann
- Applicant: INNATE PHARMA
- Applicant Address: FR Marseilles
- Assignee: INNATE PHARMA
- Current Assignee: INNATE PHARMA
- Current Assignee Address: FR Marseilles
- Agency: Saliwanchik, Lloyd & Eisenschenk
- International Application: PCT/EP2015/071069 WO 20150915
- International Announcement: WO2016/041945 WO 20160324
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C07K16/30 ; A61K39/00
Abstract:
The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
Public/Granted literature
- US20170291947A1 NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES Public/Granted day:2017-10-12
Information query
